EpimAb Biotherapeutics

19 articles with EpimAb Biotherapeutics

• EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer

  6/7/2022

  EpimAb Biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase Ib/II study in patients with non-small cell lung cancer (NSCLC) evaluating the combination of EMB-01, a bispecific antibody designed to simultaneously target EGFR and cMET on tumor cells, and Tagrisso® (osimertinib).

• EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Andrew X. Zhu

  10/12/2021

  EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibodies, today announced the appointment of Andrew X. Zhu, M.D., Ph.D., to the company’s Scientific Advisory Board.

• EpimAb Biotherapeutics Provides Clinical Update for EMB-02 and EMB-06

  7/7/2021

  EpimAb Biotherapeutics, today announced dose administration for the first patient in a Phase 1/2 clinical trial of EMB-02, a bispecific antibody targeting PD-1 and LAG-3, in patients with advanced solid tumors, as well as in a Phase 1/2 clinical trial of EMB-06, a bispecific antibody targeting B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3), in patients with recurrent and refractory multiple myeloma.

• 

  Money on the Move: March 17-23

  3/24/2021

  It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
• 

  News Brief – FDA Slapdown, Patent Approval, Funding News and More

  3/23/2021

  The life sciences industry is a bustling beehive of activity. Here’s a quick compilation of some of today’s newsworthy announcements.  

• EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor

  9/15/2020

  IND filing of second bispecific antibody candidate developed from EpimAb’s FIT-Ig® platform

• EpimAb Biotherapeutics Strengthens Scientific Advisory Board with Addition of Professor Mark Smyth

  7/24/2020

  EpimAb Biotherapeutics announced the appointment of Professor Mark Smyth to the company’s Scientific Advisory Board. Currently a Senior Scientist and the Immunology Department Coordinator at QIMR Berghofer Medical Research Institute, Professor Smyth brings over 20 years of immuno-oncology expertise and research experience to the Scientific Advisory Board.

• EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II

  6/22/2020

  EpimAb Biotherapeutics , an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today presented preclinical data at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II. The data presented in the poster titled, “ EMB-01: An innovative bispecific antibody targeting EGFR and c

• EpimAb Biotherapeutics and QIMR Berghofer Medical Research Institute Announce Research Collaboration and License Agreement on Novel Bispecific Target Combinations

  4/23/2020

  EpimAb receives exclusive access to newly discovered target combinations in order to expand its proprietary pipeline

• EpimAb Biotherapeutics Appoints David Gu, Ph.D. as New Chief Financial Officer to Drive Corporate Development Plans

  3/24/2020

  EpimAb Biotherapeutics announced the appointment of Dr. Xinyi “David” Gu as the new Chief Financial Officer of EpimAb, adding to the current leadership team consisting of Chengbin Wu, Ph.D. CEO; Stephan Lensky, Ph.D. COO and CBO; and Bin Peng, M.D., Ph.D., CMO. Dr. Gu joins EpimAb from Millennium Management where he oversaw investments in global pharmaceutical and biotechnology companies.

• EpimAb Biotherapeutics Raises $74M in Series B Financing

  6/5/2019

  Funding to be used in growing and advancing the Company’s clinical pipeline of novel bispecific antibodies

• 

  China's EpimAb Biotherapeutics Raises $74 Million in Series B to Advance Solid Tumor Therapy

  6/5/2019

  EpimAb plans to use the funds to advance its Phase I/II clinical program, EMB01, expand its clinical pipeline into immuno-oncology and other areas and add a new manufacturing site in Suzhou for process development and pilot manufacturing.

• EpimAb Biotherapeutics is Granted US Patent on Core Bispecific Antibody Technology

  4/24/2019

  Patent protects EpimAb’s core technology FIT-Ig® and its entire bispecific pipeline with a broad composition of matter claim

• EpimAb Biotherapeutics Achieves Key Milestone with Lead Cancer Program EMB01

  1/29/2019

  First Patients Dosed with Company’s Novel Bispecific Antibody Format in Phase I/II Clinical Trial

• EpimAb Biotherapeutics Announces IND Filing for EMB01 in China and the US

  9/14/2018

  IND Filing Marks Further Progress Towards the First Clinical Trial with the Company’s Novel Bispecific Antibody Format

• EpimAb Biotherapeutics Appoints Industry Veteran Bin Peng as Chief Medical Officer

  2/27/2018

  EpimAb Biotherapeutics, a biologics company based in Shanghai, China, specialized in developing a portfolio of bispecific antibodies, announced today that Bin Peng, MD, PhD, has joined the company as its first Chief Medical Officer.

• EpimAb Biotherapeutics Collaborates With Wuxi Biologics To Advance Lead Bispecific Antibody Candidate Towards Clinical Development

  5/31/2017

• EpimAb Biotherapeutics Raises $25M In Series A Financing From International Consortium To Advance Pipeline Of Novel Bispecific Antibodies

  4/25/2017

• Kymab And EpimAb Biotherapeutics Announce Multi-Target, Bispecific Antibody Cross-Licensing Agreement

  10/11/2016